Personalized cancer immunotherapy for aggressive hypoxic tumors with blockbuster potential.
Our Target Mechanism For Treating Hypoxic Tumors: Carbonic Anhydrase IX (CA IX).
Our Mission:
- to fill the gap in treatment of oncology diseases with poor prognosis,
- to increase survival rate and bring hope to patients who have undergone different types of therapies without success,
- to deliver novel therapeutics that match the principle of personalized medicine which will help patients to improve the quality of their lives.
Crunchbase
https://www.crunchbase.com/organization/mabpro-therapeutics
Company Details
- Employees
- 11
- Founded
- -
- Address
- Dúbravská Cesta 2, Bratislava,slovakia 84104,slovakia
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.mabpro.sk
- Keywords
- IT Consulting.
- HQ
- Bratislava, Slovakia
Mabpro Therapeutics Questions
Mabpro Therapeutics's website is http://www.mabpro.sk
Mabpro Therapeutics's LinkedIn profile is https://sk.linkedin.com/company/mabprotx
Mabpro Therapeutics has
11 employees.
View email and phone details for 11
employees at Mabpro Therapeutics.
Mabpro Therapeutics's industry is
Biotechnology Research
Mabpro Therapeutics's top competitors are
Insar.sk,
Greencorp,
Medic Cells S.r.o.,
Schwabe Slovakia,
Avansource,
Sapientis Biologics,
Covariate,
Memmert Central Europe S.r.o.,
Medic Labor,
Roche Slovensko.
Mabpro Therapeutics's categories are Biotechnology Research
Mabpro Therapeutics's founding year is 2016
